Home
Storia in 2 fonti
A Series A, B and an IPO; Cabaletta reports CAR-T results
Degron Therapeutics has collected an additional $40 million for its molecular glue degrader platform; CREATE Medicines raises $122 million; and more
- ·
statnews.com
CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million
CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates through human trials.
- ·
endpoints.news
A Series A, B and an IPO; Cabaletta reports CAR-T results
Degron Therapeutics has collected an additional $40 million for its molecular glue degrader platform; CREATE Medicines raises $122 million; and more